Esperion's Bempedoic Acid Gains ACC Approval: Navigating Financial Challenges and Market Sentiment.

Esperion Therapeutics has received approval for bempedoic acid in new ACC guidelines as a primary option for lowering LDL-C in high-risk patients. Despite this endorsement, the company faces financial challenges, including a negative Altman Z-Score indicating potential distress. Esperion's financial health presents a mixed picture, with a revenue decline and negative net margin. The company's valuation metrics suggest a speculative growth profile, but investors should consider financial health grades, sector-specific risks, and volatility.